All In MedTech

Device Trial Radar · NCT04503564

"FEXIS": (Feasibility of an Extended Wear CSII Set in Participants With T1DM)

Feasibility of an Investigational Extended Wear Infusion Set for Continuous Subcutaneous Insulin Infusion (CSII) in Type 1 Diabetes Mellitus (T1DM) Participants

Last checked: Nov 20, 2026Latest source record: Mar 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

20

Actual

Start

Nov 13, 2019

Primary completion

Nov 11, 2020

Study completion Nov 11, 2020

Sponsor

Lead sponsor
Capillary Biomedical, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Aug 7, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Device feasibility
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Over 1 million patients globally currently manage their Type 1 Diabetes mellitus using continuous subcutaneous insulin infusion with an infusion set that needs to be changed every 3 days. This study will assess the feasibility and device performance of the study device, the Achilles infusion set over three periods during routine insulin infusion. This study will include 20 participants and has 3 periods: Period 1 (up to 7 days): Trial run with study device with saline infusion. Period 2 (up to 7 days): participants will manage their blood glucose solely with their insulin pump and the Achilles infusion set. Blood glucose will be closely monitored with a continuous glucose monitoring (CGM) device. Period 3 (up to 7 days): Participants will return to study center to receive a fresh Achilles infusion set and continue blood glucose management at home until infusion set failure or 7 days.

Conditions

  • Diabetes Mellitus, Type 1
  • Type 1 Diabetes
  • Type 1 Diabetes Mellitus
  • Diabetes Mellitus, Insulin-Dependent, 1

Interventions

  • coil-reinforced soft polymer indwelling cannulaDevice

    This is a prospective, non-randomized, home-use feasibility study of device performance, usability, tolerability, and safety of the Capillary Biomedical, Inc. (CapBio) Achilles infusion set for continuous subcutaneous insulin infusion (CSII or insulin pump therapy) in up to 20 participants diagnosed with type 1 diabetes mellitus (T1DM).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Infusion Set Survival at End of Day 7Time frame: 7 days during weeks 2 and 3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St Vincent's Hospital (Melbourne) Ltd - Fitzroy

    Melbourne, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.